share_log

Is Meinian Onehealth Healthcare Holdings Co., Ltd.'s (SZSE:002044) Stock On A Downtrend As A Result Of Its Poor Financials?

Is Meinian Onehealth Healthcare Holdings Co., Ltd.'s (SZSE:002044) Stock On A Downtrend As A Result Of Its Poor Financials?

是美年萬健醫療控股有限公司嗎s (SZSE: 002044) 由於財務狀況不佳,股票處於下跌趨勢?
Simply Wall St ·  04/02 18:55

It is hard to get excited after looking at Meinian Onehealth Healthcare Holdings' (SZSE:002044) recent performance, when its stock has declined 16% over the past three months. We decided to study the company's financials to determine if the downtrend will continue as the long-term performance of a company usually dictates market outcomes. Particularly, we will be paying attention to Meinian Onehealth Healthcare Holdings' ROE today.

看了美年Onehealth Healthcare Holdings(深圳證券交易所:002044)最近的表現,很難感到興奮,當時其股票在過去三個月中下跌了16%。我們決定研究公司的財務狀況,以確定下跌趨勢是否會繼續,因爲公司的長期表現通常決定市場業績。特別是,我們今天將關注美年Onehealth Healthcare Holdings的投資回報率。

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.

股本回報率或投資回報率是用於評估公司管理層利用公司資本效率的關鍵指標。簡而言之,它衡量公司相對於股東權益的盈利能力。

How Do You Calculate Return On Equity?

你如何計算股本回報率?

The formula for ROE is:

ROE 的公式是:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回報率 = 淨利潤(來自持續經營業務)÷ 股東權益

So, based on the above formula, the ROE for Meinian Onehealth Healthcare Holdings is:

因此,根據上述公式,美年Onehealth Healthcare Holdings的投資回報率爲:

2.4% = CN¥205m ÷ CN¥8.4b (Based on the trailing twelve months to September 2023).

2.4% = 2.05億元人民幣 ÷ 84億元人民幣(基於截至2023年9月的過去十二個月)。

The 'return' is the amount earned after tax over the last twelve months. So, this means that for every CN¥1 of its shareholder's investments, the company generates a profit of CN¥0.02.

“申報表” 是過去十二個月的稅後收入金額。因此,這意味着其股東每投資1元人民幣,公司就會產生0.02元人民幣的利潤。

What Has ROE Got To Do With Earnings Growth?

投資回報率與收益增長有什麼關係?

So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.

到目前爲止,我們已經了解到,投資回報率是衡量公司盈利能力的指標。然後,我們能夠評估公司的收益增長潛力,具體取決於公司對這些利潤進行再投資或 “保留” 了多少及其有效性。一般而言,在其他條件相同的情況下,股本回報率和利潤留存率高的公司的增長率要高於不具有這些屬性的公司。

Meinian Onehealth Healthcare Holdings' Earnings Growth And 2.4% ROE

美年萬健醫療控股的收益增長和2.4%的投資回報率

As you can see, Meinian Onehealth Healthcare Holdings' ROE looks pretty weak. Not just that, even compared to the industry average of 7.9%, the company's ROE is entirely unremarkable. Therefore, it might not be wrong to say that the five year net income decline of 12% seen by Meinian Onehealth Healthcare Holdings was possibly a result of it having a lower ROE. We reckon that there could also be other factors at play here. Such as - low earnings retention or poor allocation of capital.

如你所見,美年OneHealth Healthcare Holdings的投資回報率看起來相當疲軟。不僅如此,即使與7.9%的行業平均水平相比,該公司的投資回報率也完全不引人注目。因此,說美年Onehealth Healthcare Holdings的五年淨收入下降12%可能是其投資回報率下降的結果,這可能沒有錯。我們認爲,這裏可能還有其他因素在起作用。例如——收益留存率低或資本配置不善。

So, as a next step, we compared Meinian Onehealth Healthcare Holdings' performance against the industry and were disappointed to discover that while the company has been shrinking its earnings, the industry has been growing its earnings at a rate of 7.0% over the last few years.

因此,下一步,我們將美年Onehealth Healthcare Holdings的表現與行業進行了比較,失望地發現,儘管該公司一直在縮減收益,但該行業在過去幾年中一直以7.0%的速度增長。

past-earnings-growth
SZSE:002044 Past Earnings Growth April 2nd 2024
SZSE: 002044 過去的收益增長 2024 年 4 月 2 日

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. Has the market priced in the future outlook for 002044? You can find out in our latest intrinsic value infographic research report.

爲公司附加價值的基礎在很大程度上與其收益增長息息相關。投資者接下來需要確定的是,預期的收益增長或缺乏收益是否已經包含在股價中。然後,這可以幫助他們確定股票是面向光明還是暗淡的未來。市場對002044的未來展望進行了定價嗎?您可以在我們最新的內在價值信息圖研究報告中找到答案。

Is Meinian Onehealth Healthcare Holdings Efficiently Re-investing Its Profits?

美年萬健醫療控股公司是否有效地將其利潤再投資?

Meinian Onehealth Healthcare Holdings has a high three-year median payout ratio of 51% (that is, it is retaining 49% of its profits). This suggests that the company is paying most of its profits as dividends to its shareholders. This goes some way in explaining why its earnings have been shrinking. With only very little left to reinvest into the business, growth in earnings is far from likely.

美年Onehealth Healthcare Holdings的三年派息率中位數很高,爲51%(也就是說,它保留了49%的利潤)。這表明該公司將大部分利潤作爲股息支付給股東。這在某種程度上解釋了其收益爲何萎縮。由於對該業務的再投資所剩無幾,收益增長的可能性很小。

Additionally, Meinian Onehealth Healthcare Holdings has paid dividends over a period of seven years, which means that the company's management is rather focused on keeping up its dividend payments, regardless of the shrinking earnings.

此外,美年Onehealth Healthcare Holdings已在七年內派發了股息,這意味着無論收益如何萎縮,該公司的管理層都相當專注於維持股息支付。

Summary

摘要

In total, we would have a hard think before deciding on any investment action concerning Meinian Onehealth Healthcare Holdings. As a result of its low ROE and lack of much reinvestment into the business, the company has seen a disappointing earnings growth rate. Having said that, looking at current analyst estimates, we found that the company's earnings growth rate is expected to see a huge improvement. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

總的來說,在決定對美年Onehealth Healthcare Holdings採取任何投資行動之前,我們會經過深思熟慮。由於投資回報率低且缺乏對該業務的再投資,該公司的收益增長率令人失望。話雖如此,從分析師目前的估計來看,我們發現該公司的收益增長率預計將出現巨大改善。這些分析師的預期是基於對該行業的廣泛預期,還是基於公司的基本面?點擊此處進入我們分析師對公司的預測頁面。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論